ARQL News and Press, ArQule Inc. From 10/30/19

Image source: The Motley Fool. Arqule Inc   (NASDAQ: ARQL) Q3 2019 Earnings Call Oct 30, 2019 , 9:00 a.m. ET Operator Continue reading

ArQule, Inc. (ARQL) Q3 2019 Earnings Conference Call October 30, 2019, 09:00 AM ET Company Participants Marc Schegerin - CFO Paolo Pucci - CEO Peter Lawrence - President and COO Brian Schwartz - Head of R&D Conference Call Participants Jonathan Chang - SVB Leerink V...

ArQule (NASDAQ: ARQL ): Q3 GAAP EPS of -$0.09 in-line. More news on: ArQule, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Conference call scheduled today at 9:00 a.m. ET ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2019. For the quarter ended September 30, 2019, the Company reported a net loss of $10.7 million, or $0.09 per basic share, compared with net...

Data from a phase 1 clinical trial suggest that circulating tumor DNA (ctDNA) may serve as a reliable biomarker of tumor mutational status and could be used to predict treatment response Preclinical work demonstrates treatment with ARQ 751 in combination with a variety of therapeutic a...

Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...

Treatment with miransertib prevents formation of new PIK3CA-driven vascular malformations and leads to regression of existing PIK3CA-driven vascular malformations in experimental mouse model ArQule , Inc. (Nasdaq: ARQL), today announced preclinical data demonstrating the potential for...

ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter of 2019 before the market opens on Wednesday, October 30, 2019. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a gener...

Two poster presentations on ARQ 751 will highlight data from the phase 1 trial, as well as preclinical studies demonstrating the potential of ARQ 751 in combination with various therapeutic agents ArQule , Inc. (Nasdaq: ARQL) today announced that it will be presenting data on the comp...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to...